Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Investment Tools And Research To Help Make You A More Confident And Profitable Trader. FREE 30 Day Trial
Stocks | Futures | Watchlist | More
or

Replicel Life Sciences Inc (RP.VN)

Replicel Life Sciences Inc (RP.VN)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [TSX Venture]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [TSX Venture]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]

Fundamentals

See More
  • Market Capitalization, $K 3,575
  • Shares Outstanding, K 65,002
  • Annual Sales, $ 354 K
  • Annual Income, $ -743 K
  • 60-Month Beta -0.08
  • Price/Sales 7.19
  • Price/Cash Flow N/A
  • Price/Book N/A
Trade RP.VN with:
  • Price/Earnings ttm N/A
  • Earnings Per Share ttm -0.02
  • Most Recent Earnings $-0.01 on N/A
  • Latest Earnings Date N/A
  • Annual Dividend & Yield N/A (N/A)
  • Most Recent Dividend N/A on N/A
  • Sectors:

Price Performance

See More
Period Period Low Period High Performance
1-Month
0.050 +10.00%
on 03/01/24
0.070 -21.43%
on 03/01/24
-0.015 (-21.43%)
since 02/08/24
3-Month
0.050 +10.00%
on 03/01/24
0.095 -42.11%
on 12/18/23
-0.030 (-35.29%)
since 12/12/23
52-Week
0.040 +37.50%
on 12/07/23
0.250 -78.00%
on 06/09/23
-0.115 (-67.65%)
since 03/06/23

Most Recent Stories

More News
RealPage Awarded 2023 ENERGY STAR Partner of the Year for Sustained Excellence

RealPage , a leading global provider of software and data analytics to the real estate industry, is proud to announce that it has received a 2023 ENERGY STAR ® Partner of the Year Award for Sustained...

RP.VN : 0.055 (unch)
CORRECTION: Independent Laboratory Test Results Confirm Value of DermaPreciseTM Injection Consistency in Clinical Simulation Testing

This press release replaces the press release disseminated July 26, 2022 at 06:00 EDT. The press release contained the wrong image - one intended for a future press release. The corrected press release...

REPCF : 0.0428 (+4.90%)
RP.VN : 0.055 (unch)
Independent Laboratory Test Results Confirm Value of DermaPrecise (TM) Injection Consistency in Clinical Simulation Testing

Independent dermatology research experts at Monasterium Laboratory GmbH tested, analyzed and validated various injection parameters using donated human tissue

REPCF : 0.0428 (+4.90%)
RP.VN : 0.055 (unch)
RepliCel Announces Material Patent Milestones

New DermaPreciseâ„¢ patent application and patents granted for tendinopathy and skin rejuvenation technologies in key markets VANCOUVER, BC / ACCESSWIRE / January 10, 2022 / RepliCel Life Sciences Inc....

REPCF : 0.0428 (+4.90%)
RP.VN : 0.055 (unch)
RepliCel Closed Final Tranche of Strategic Investment Commitment

VANCOUVER, BC / ACCESSWIRE / December 21, 2021 / RepliCel Life Sciences Inc. (OTC PINK:REPCF) (TSXV:RP) (FRA:P6P2) ("RepliCel" or the "Company"), a company developing next-generation technologies in aesthetics...

REPCF : 0.0428 (+4.90%)
RP.VN : 0.055 (unch)
RepliCel Terminates License Agreement with Shiseido

VANCOUVER, BC / ACCESSWIRE / December 21, 2021 / RepliCel Life Sciences Inc. (OTC PINK:REPCF)(TSXV:RP)(FSE:P6P2) ("RepliCel" or the "Company"), a company developing next-generation technologies in aesthetics...

REPCF : 0.0428 (+4.90%)
RP.VN : 0.055 (unch)
RealPage Agrees to Acquire HomeWiseDocs, The Premier Provider of Disclosure Management Services to the Community Association Industry

RealPage, Inc., a leading global provider of software and data analytics to the real estate industry, today announced that it has entered into a definitive agreement to acquire HomeWiseDocs, a leading...

RP.VN : 0.055 (unch)
RepliCel Ships DermaPrecise(TM) Injector Prototypes and Consumables to Independent Laboratory for Clinical Simulation Testing

Independent dermatology research experts at Monasterium Laboratory GmbH will test, analyze and validate various injection parameters using donated human tissue VANCOUVER, BC / ACCESSWIRE / November 11,...

RP : 88.72 (+0.08%)
REPCF : 0.0428 (+4.90%)
RP.VN : 0.055 (unch)
RepliCel’s Clinical Advisory Team Delivers Skin Rejuvenation Clinical Study Synopsis to its Japanese Regulatory and Clinical Study Management Team

RepliCel's CRO and regulatory advisors now begin preparing Japanese-language documentation to support study clearance VANCOUVER, BC / ACCESSWIRE / November 9, 2021 / RepliCel Life Sciences Inc. (OTCQB:REPCF)(TSXV:RP)(FRA:P6P2)...

REPCF : 0.0428 (+4.90%)
RP.VN : 0.055 (unch)
RepliCel Announces DermaPrecise Trademark for Dermal Injector Product Line

Trademark registrations kickoff pre-commercial planning VANCOUVER, BC / ACCESSWIRE / October 28, 2021 / RepliCel Life Sciences Inc. (OTC PINK:REPCF)(TSXV:RP)(FRA:P6P2) ("RepliCel" or the "Company"), a...

REPCF : 0.0428 (+4.90%)
RP.VN : 0.055 (unch)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 88% Sell with a Average short term outlook on maintaining the current direction.

See More Share

Business Summary

RepliCel Life Sciences Inc is a Canadian regenerative medicine company. It focuses on developing autologous cell therapies that treat functional cellular deficits. The company addresses various diseases such as chronic tendon injuries, androgenetic alopecia, and skin aging. Its development program of...

See More

Key Turning Points

3rd Resistance Point 0.055
2nd Resistance Point 0.055
1st Resistance Point 0.055
Last Price 0.055
1st Support Level 0.055
2nd Support Level 0.055
3rd Support Level 0.055

See More

52-Week High 0.250
Fibonacci 61.8% 0.170
Fibonacci 50% 0.145
Fibonacci 38.2% 0.120
Last Price 0.055
52-Week Low 0.040

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar